Whole-Genome Sequencing in Pharmacogenetics

Abstract

PharmacogenomicsVol. 14, No. 4 EditorialWhole-genome sequencing in pharmacogeneticsThomas J UrbanThomas J UrbanCenter for Human Genome Variation, Duke University Medical Center, 308 Research Drive, LSRC Wing B, Room 331A, Durham, NC 27708-1009, USA. Search for more papers by this authorEmail the corresponding author at thomas.urban@duke.eduPublished Online:25 Feb 2013https://doi.org/10.2217/pgs.12.211AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: clinical sequencingdrug developmentnext-generation sequencingNGSpharmacogenomicsWESWGSwhole-exome sequencingReferences1 Maher B. Personal genomes: the case of the missing heritability. Nature456(7218),18–21 (2008).Crossref, Medline, CAS, Google Scholar2 Goldstein DB. Common genetic variation and human traits. N. Engl. J. Med.360(17),1696–1698 (2009).Crossref, Medline, CAS, Google Scholar3 Link E, Parish S, Armitage J et al.SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8),789–799 (2008).Crossref, Medline, CAS, Google Scholar4 Daly AK, Donaldson PT, Bhatnagar P et al.HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet.41(7),816–819 (2009).Crossref, Medline, CAS, Google Scholar5 Rabbani B, Mahdieh N, Hosomichi K et al. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J. Hum. Genet.57(10),621–632 (2012).Crossref, Medline, CAS, Google Scholar6 Xu B, Ionita-Laza I, Roos JL et al.De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat. Genet.44(12),1365–1369 (2012).Crossref, Medline, CAS, Google Scholar7 Holm H, Gudbjartsson DF, Sulem P et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat. Genet.43(4),316–320 (2011).Crossref, Medline, CAS, Google Scholar8 Durbin RM, Abecasis GR, Altshuler DL et al. A map of human genome variation from population-scale sequencing. Nature467(7319),1061–1073 (2010).Crossref, Medline, CAS, Google Scholar9 Zhu M, Need AC, Han Y et al. Using ERDS to infer copy-number variants in high-coverage genomes. Am. J. Hum. Genet.91(3),408–421 (2012).Crossref, Medline, CAS, Google Scholar10 Johansson I, Lundqvist E, Bertilsson L et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA90(24),11825–11829 (1993).Crossref, Medline, CAS, Google Scholar11 Lucena MI, Molokhia M, Shen Y et al. Susceptibility to amoxicillin–clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011).Medline, Google Scholar12 McCormack M, Alfirevic A, Bourgeois S et al.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med.364(12),1134–1143 (2011).Crossref, Medline, CAS, Google Scholar13 Spraggs CF, Budde LR, Briley LP et al.HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol.29(6),667–673 (2011).Crossref, Medline, CAS, Google Scholar14 Bamshad MJ, Ng SB, Bigham AW et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet.12(11),745–755 (2011).Crossref, Medline, CAS, Google Scholar15 von Bubnoff A. Next-generation sequencing: the race is on. Cell132(5),721–723 (2008).Crossref, Medline, CAS, Google Scholar16 Ong FS, Deignan JL, Kuo JZ et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics13(4),465–475 (2012).Link, CAS, Google Scholar101 Hindorff, LA, MacArthur J, Morales J et al. National Human Genome Research Institute (NHGRI). A catalog of published genome-wide association studies. www.genome.gov/gwastudies (Accessed 12 September 2012)Google ScholarFiguresReferencesRelatedDetailsCited BySimPEL: Simulation-based power estimation for sequencing studies of low-prevalence conditions22 May 2018 | Genetic Epidemiology, Vol. 42, No. 5Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences31 May 2016 | The Pharmacogenomics Journal, Vol. 17, No. 5Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementationMethods, Vol. 110Impact of New Genomic Technologies on Understanding Adverse Drug Reactions14 September 2015 | Clinical Pharmacokinetics, Vol. 55, No. 4An extension of fuzzy topological approach for comparison of genetic sequencesJournal of Intelligent & Fuzzy Systems, Vol. 29, No. 5Roadmap to Drug Development Enabled by Pharmacogenetics25 June 2015Constitutional DisordersDo genetic polymorphisms alter patient response to inhaled bronchodilators?7 August 2014 | Expert Opinion on Drug Metabolism & Toxicology, Vol. 10, No. 9Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug ReactionsAnnual Review of Genomics and Human Genetics, Vol. 15, No. 1Pharmacogenetic considerations for acute lymphoblastic leukemia therapies27 March 2014 | Expert Opinion on Drug Metabolism & Toxicology, Vol. 10, No. 5Pharmacogenomics of Osteoporotic Fractures3 July 2014Drug-induced Acute Liver FailureClinics in Liver Disease, Vol. 17, No. 4To Replicate or Not to Replicate: The Case of Pharmacogenetic StudiesCirculation: Cardiovascular Genetics, Vol. 6, No. 4 Vol. 14, No. 4 Follow us on social media for the latest updates Metrics Downloaded 717 times History Published online 25 February 2013 Published in print March 2013 Information© Future Medicine LtdKeywordsclinical sequencingdrug developmentnext-generation sequencingNGSpharmacogenomicsWESWGSwhole-exome sequencingFinancial & competing interests disclosureWork on this article was supported by a grant from the NIH: 2U01-DK065201-10. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download